Please enable Javascript
Non-Muscle Invasive Urothelial Carcinoma
Advertisement
Addressing the BCG Shortage: Gemcitabine/Docetaxel Is an Effective Substitute Treatment for NMIBC
Vignesh Packiam, MD
Non-Muscle Invasive Urothelial Carcinoma
|
March 22, 2023
Vignesh T. Packiam, MD discusses the current BCG shortage as well as potential substitutes such as gemcitabine and docetaxel.
Read More
IFNα With Nadofaragene Firadenovec Shows Clinical Efficacy for NMIBC
Emily Menendez
Non-Muscle Invasive Urothelial Carcinoma
|
February 27, 2023
IFNα and nadofaragene firadenovec can provide a new therapy approach for a disease with a significant unmet clinical need.
Read More
IL-15 Superagonist for Treatment of BCG-unresponsive Non-muscle Invasive Bladder Cancer
Akhil Abraham Saji, MD
Non-Muscle Invasive Urothelial Carcinoma
|
February 24, 2023
BCG plus nogapendekin alfa inbakicept may offer an enhanced treatment option for patients with high-risk NMIBC.
Read More
KEYNOTE-057: Pembrolizumab Monotherapy for High-risk NMIBC Unresponsive to BCG
Andrea Necchi, MD
ASCO GU Symposium 2023
|
February 18, 2023
Andrea Necchi, MD, speculates on the applicability of pembrolizumab monotherapy for BCG-unresponsive NMIBC.
View More
Detecting MRD Prior to Repeat-transurethral Resection of Bladder Tumor in NMIBC
Kyle M. Rose, MD
ASCO GU Symposium 2023
|
February 18, 2023
Kyle M. Rose, MD, describes how cell-free DNA is used to detect MRD prior to repeat-transurethral resection in NMIBC.
View More
Treatment Patterns and Adherence to BCG for Patients With High-Risk NMIBC
Emily Menendez
ASCO GU Symposium 2023
|
February 17, 2023
A recent study analyzed the effectiveness of BCG treatment in patients with NMIBC, including a subgroup of patients with CIS.
Read More
Joshua Meeks, MD, PhD – Targeting Unmet Need in Urothelial Carcinoma
Joshua Meeks, MD, PhD
Non-Muscle Invasive Urothelial Carcinoma
|
January 27, 2023
Joshua Meeks, MD, PhD, discusses ongoing research in NMIBC and the future of urothelial carcinoma care.
Read More
Safety and Efficacy of Intravesical Mitomycin C for Pre-Transurethral Resection of Bladder Tumors
Emily Menendez
Non-Muscle Invasive Urothelial Carcinoma
|
January 25, 2023
Researchers developed a randomized phase II clinical trial for patients with NMIBC before transurethral resection of tumors.
Read More
Gene Therapy for Non-Muscle-Invasive Bladder Cancer: A New Era of Treatment
Colin Dinney, MD
Expert Interviews
|
January 5, 2023
Colin Dinney, MD, explains the data that led to FDA approval of Adstiladrin for NMIBC and how it impacts the treatment.
Read More
Use of Neoadjuvant Intravesical Therapy for NMIBC
David Ambinder, MD
Journal
|
December 19, 2022
By administering immediate single-dose intravesical chemotherapy, there is a 15% absolute risk reduction in tumor recurrence.
Read More
First Gene Therapy Approved for the Treatment of High-Risk, Non-Muscle-Invasive Bladder Cancer
Zachary Bessette
Non-Muscle Invasive Urothelial Carcinoma
|
December 19, 2022
The FDA approved Adstiladrin, a gene therapy for the treatment of adult patients with high-risk BCG-unresponsive NMIBC.
Read More
Balloon Cryoablation Non-inferior to Single Instillation of Chemotherapy in NMIBC
Leah Lawrence
Non-Muscle Invasive Urothelial Carcinoma
|
December 13, 2022
Endoscopic balloon cryoablation is an effective therapy for transurethral resection of non-muscle invasive bladder cancer.
Read More
A Review of the PHOTO Trial Publication
David Ambinder, MD
Journal
|
November 22, 2022
The multicenter phase 3 randomized controlled PHOTO trial examined if blue light cystoscopy could improve patient outcomes.
Read More
Trial Results of Microparticle Docetaxel for High-Risk NMIBC
David Ambinder, MD
Journal
|
November 22, 2022
A study analyzing the safety and efficacy of large surface area microparticle docetaxel for NMIBC is reviewed.
Read More
Intravesical Immunotherapy in the Management of NMIBC
David Ambinder, MD
Journal
|
October 24, 2022
Researchers evaluated the safety and efficacy of intravesical pembrolizumab when in conjunction with intravesical BCG.
Read More
Primary Chemoresection Effective for Small Recurrent NMIBC
Leah Lawrence
Non-Muscle Invasive Urothelial Carcinoma
|
October 18, 2022
Short-term intensive chemoresection, a nonsurgical treatment modality, treated recurrent NMIBC, reducing required procedures.
Read More
Lymphocyte-to-Monocyte Ratio During BCG Induction Independently Predicts NMIBC Prognosis
Cecilia Brown
Non-Muscle Invasive Urothelial Carcinoma
|
August 8, 2022
The induction lymphocyte-to-monocyte ratio was associated with “better accuracy” and than the preoperative ratio.
Read More
Gemcitabine Plus Docetaxel: An Effective Alternative to BCG Therapy for High-Risk NMIBC
Cecilia Brown
Non-Muscle Invasive Urothelial Carcinoma
|
July 29, 2022
While BCG has been the standard adjuvant therapy for patients with high-risk NMIBC, a shortage has led to other regimens.
Read More
Intravesical BCG Is the Current Standard of Care for Patients With NMIBC
David Ambinder, MD
Journal
|
July 27, 2022
The current standard of care for patients with high-grade NMIBC, intravesical Bacillus Calmette-Guérin, is discussed.
Read More
No Impact of Germline Variants on RFS, PFS in NMIBC Patients Receiving Bacillus Calmette-Guerin
Cecilia Brown
Non-Muscle Invasive Urothelial Carcinoma
|
July 26, 2022
Pathogenic variants were more common in patients who had high-grade NMIBC than in patients with low-grade NMIBC.
Read More
Load More
Advertisement
Advertisement
Advertisement